Frontal-subcortical volumetric deficits in single episode, medication-naïve depressed patients and the effects of 8 weeks fluoxetine treatment: a VBM-DARTEL study

PLoS One. 2014 Jan 10;9(1):e79055. doi: 10.1371/journal.pone.0079055. eCollection 2014.

Abstract

Background: Convergent studies suggest that morphological abnormalities of frontal-subcortical circuits which involved with emotional and cognitive processing may contribute to the pathophysiology of major depressive disorder (MDD). Antidepressant treatment which has been reported to reverse the functional abnormalities of frontal-subcortical circuits in MDD may have treating effects to related brain morphological abnormalities. In this study, we used voxel-based morphometry method to investigate whole brain structural abnormalities in single episode, medication-naïve MDD patients. Furthermore, we investigated the effects of an 8 weeks pharmacotherapy with fluoxetine.

Methods: 28 single episode, medication-naïve MDD participants and 28 healthy controls (HC) acquired the baseline high-resolution structural magnetic resonance imaging (sMRI) scan. 24 MDD participants acquired a follow-up sMRI scan after 8 weeks antidepressant treatment. Gray matter volumetric (GMV) difference between groups was examined.

Results: Medication-naïve MDD had significantly decreased GMV in the right dorsolateral prefrontal cortex and left middle frontal gyrus as well as increased GMV in the left thalamus and right insula compared to HC (P<0.05, corrected). Moreover, treated MDD had significantly increased GMV in the left middle frontal gyrus and right orbitofrontal cortex compared to HC (P<0.05, corrected). No difference on GMV was detected between medication-naïve MDD group and treated MDD group.

Conclusions: This study of single episode, medication-naïve MDD subjects demonstrated structural abnormalities of frontal-subcortical circuitsin the early stage of MDD and the effects of 8 weeks successful antidepressant treatment, suggesting these abnormalities may play an important role in the neuropathophysiology of MDD at its onset.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antidepressive Agents, Second-Generation / therapeutic use
  • Brain / pathology
  • Case-Control Studies
  • Cerebral Cortex / pathology*
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / pathology*
  • Female
  • Fluoxetine / therapeutic use*
  • Follow-Up Studies
  • Frontal Lobe / pathology*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Organ Size
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • Antidepressive Agents, Second-Generation
  • Serotonin Uptake Inhibitors
  • Fluoxetine

Grants and funding

This study was supported by the National Natural Science Foundation of China (Grant No 81101012, 81071099), the Liaoning Doctor Scientific Foundation (Grant No 20111099), the Liaoning Science and Technology Foundation (Grant No 2008225010-14). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.